<DOC>
	<DOCNO>NCT00414128</DOCNO>
	<brief_summary>The purpose study investigate whether mycophenolate mofetil effective treatment new case ANCA associate vasculitis .</brief_summary>
	<brief_title>Clinical Trial Mycophenolate Versus Cyclophosphamide ANCA Vasculitis</brief_title>
	<detailed_description>There clear need improve therapy ANCA associate vasculitis current treatment toxic contribute poor outcome . Conventional therapy combine cyclophosphamide prednisolone associate severe adverse event 35 % , early mortality , malignancy infertility . Mycophenolate mofetil ( MMF ) newer immunosuppressive drug superior efficacy azathioprine solid organ transplantation . MMF effective alternative cyclophosphamide lupus nephritis . Open label study retrospective survey point efficacy low toxicity MMF vasculitis . We hypothesise MMF less effective cyclophosphamide remission induction AASV . 140 new patient randomise MMF 3g/day European consensus intravenous cyclophosphamide regimen , prednisolone dosing . Following six month induction course patient receive consensus remission maintenance treatment azathioprine prednisolone . The primary end-point remission rate six month , secondary end-points include relapse rate 18 month safety . The trial conduct 10 country member European Vasculitis Study Group ( EUVAS ) . The trial duration 42 month ( 24 month recruitment , 18 month follow ) .</detailed_description>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Inclusion ( require ) : New diagnosis AASV ( WG MPA ) ( within previous six month ) Active disease ( define least one major three minor BVAS 2003 item , see appendix 1 ) ANCA positivity ( cANCA PR3ANCA pANCA MPOANCA ) histology confirm active vasculitis organ ( see appendix ) Written inform consent Previous treatment : MMF : two week ever . Cyclophosphamide : two week daily oral 1 pulse IV CYC ( 15mg/kg ) Rituximab high dose intravenous immunoglobulin within last twelve month Active infection ( include hepatitis B , C , HIV tuberculosis ) . Known hypersensitivity MMF , AZA CYC . Cancer individual history cancer ( resect basal cell skin carcinoma ) . Females pregnant , breast feeding , risk pregnancy use medically acceptable form contraception . Any condition judge investigator would cause study detrimental patient . Any multisystem autoimmune disease include Churg Strauss angiitis , SLE , anti GBM disease cryoglobulinaemia .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>vasculitis</keyword>
	<keyword>ANCA</keyword>
	<keyword>mycophenolate mofetil</keyword>
	<keyword>cyclophosphamide</keyword>
	<keyword>Anti neutrophil cytoplasm antibody associate vasculitis</keyword>
</DOC>